Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002534342 | SCV000826082 | uncertain significance | Pontocerebellar hypoplasia type 1A | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with cysteine at codon 103 of the VRK1 protein (p.Arg103Cys). The arginine residue is weakly conserved and there is a large physicochemical difference between arginine and cysteine. This variant is present in population databases (rs755450815, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with VRK1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003163218 | SCV003888197 | uncertain significance | Inborn genetic diseases | 2023-02-01 | criteria provided, single submitter | clinical testing | The c.307C>T (p.R103C) alteration is located in exon 5 (coding exon 4) of the VRK1 gene. This alteration results from a C to T substitution at nucleotide position 307, causing the arginine (R) at amino acid position 103 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000697470 | SCV001454081 | uncertain significance | Congenital pontocerebellar hypoplasia type 1 | 2020-09-16 | no assertion criteria provided | clinical testing |